|
|
||||||||
Thermal and Mountain Medicine Division, United States Army Research Institute of Environmental Medicine, Natick, Massachusetts 01760-5007
| |
ABSTRACT |
|---|
|
|
|---|
Fever is
defined as a regulated rise in body temperature. The regulation of this
phenomenon is accomplished by the actions of two types of endogenous
cytokines, some functioning as pyrogens and others as antipyretics.
Previous data obtained with the use of traditional pharmacological
techniques, such as the injection of neutralizing antibodies, implicate
interleukin (IL)-1 and IL-6 as endogenous pyrogens or inducers of
fever. In almost all instances in which the endogenous actions of IL-1
or IL-6 are antagonized, fevers are attenuated. Other cytokines, such
as tumor necrosis factor-
(TNF-
) and IL-10, are thought to act as
endogenous antipyretics or inhibitors of fever. In several studies, the
inhibition of TNF action has enhanced fever. Recently, mice genetically
engineered to lack cytokines or their receptors in all tissues of the
body have been used to examine the regulation of IL-1, IL-6, TNF, and IL-10 on fever. Data obtained with these mice shed new light on our
understanding of cytokine interactions in fever and, in some instances,
contradict data obtained with pharmacological methods. This review
summarizes the responses of cytokine and cytokine receptor knockout
mice to fevers induced by lipopolysaccharide, turpentine, and sepsis.
interleukin-1; interleukin-6; interleukin-10; tumor necrosis factor; thermoregulation
| |
INTRODUCTION |
|---|
|
|
|---|
FEVER IS A COMMON RESPONSE to infection, inflammation, and trauma. Clinically, fever is characterized as a rise in body temperature (Tb) above the normal range, and it is often met with attempts to eliminate it. We now understand that fever is a complex physiological response that is aimed at facilitating survival of the host. Liebermeister (25) was the first to accurately define fever as a regulated elevation in the thermal set point when he observed a return of febrile individuals to a previous level of Tb after experimental warming or cooling. This distinguishes fever from hyperthermia, which represents an unregulated rise in Tb due to an internal (e.g., exercise) or external (e.g., sauna) heat load that is not triggered by an increased set point.
Fever is the result of communication between the peripheral immune system and the brain. After contact with a pathogen or an inflammatory stimulus, macrophages and other immune cells are activated to release cytokines. Although the pathways used for signaling to the brain are still not clear, cytokines are thought to either cross the blood-brain barrier by saturated transport mechanisms (3) or interact with peripheral neural components of the immune system (e.g., vagus nerve; Ref. 42) to signal the hypothalamus to increase the thermal set point. This subsequently initiates the effector mechanisms that serve to increase Tb. Thus, in response to an infectious or inflammatory agent, an organism increases heat production and decreases heat loss in an attempt to actively elevate Tb to match the increased thermal set point. In humans, physiological and behavioral mechanisms used to increase heat production include shivering and the drinking of hot fluids, whereas heat loss is reduced by peripheral vasoconstriction and a reduction of body surface area (e.g., assuming a fetal position).
There are two types of cytokines responsible for the generation of
fever. Endogenous pyrogens are cytokines that induce fever and include
interleukin (IL)-1, IL-6, IL-8, macrophage-inflammatory protein-1
(MIP-1
), and interferon-
. The other types of cytokines are
endogenous antipyretics, which limit the magnitude and duration of
fever and include such substances as IL-10, arginine vasopressin (AVP),
-melanocyte-stimulating hormone (
-MSH), and glucocorticoids. Although AVP,
-MSH, and glucocorticoids are not true cytokines, they
still possess endogenous antipyretic properties. Other substances, such
as tumor necrosis factor-
(TNF-
), have been shown to have pyrogenic and antipyretic properties, depending on the experimental conditions. Ultimately, it is the sum of the interactions of pyrogenic and antipyretic cytokines that is responsible for the height and duration of a fever response. These cytokine interactions are dependent
on a variety of factors, including the species, the model of infection,
and the strength of the fever-inducing stimulus. Figure
1 provides a general pathway of fever
regulation involving endogenous pyrogens and antipyretics.
|
Traditionally, pharmacological techniques have been used to characterize the role of cytokines in the regulation of fever. For example, cytokines have been peripherally or centrally injected into several experimental animals and shown to induce fever. However, this effect does not warrant the conclusion that the substance functions endogenously as a pyrogen, since many substances may induce fever when injected (e.g., turpentine). Therefore, the injection of neutralizing agents has been used to examine the effect of a cytokine's antagonism on a fever response induced by a pathogen, such as lipopolysaccharide (LPS; a cell wall component of gram-negative bacteria). The advantage of this technique is that specific anatomic regions implicated in fever regulation can be targeted with the microinjection of a cytokine antagonist. The disadvantage to this method is the uncertainty as to whether the cytokine's action has been neutralized in all areas of the body that may be important for the regulation of the response. The diffusion properties and the half-life of most injected substances are not measured, and this also often makes interpretation difficult.
The recent development of gene knockout technology provides a valuable tool to extend our investigations into the role of cytokines in fever. These mice lack functional genes for cytokines or cytokine receptors in all tissues of the body. Thus one can study the effect of the absence of a cytokine's action on the fever response and compare the results with those obtained with the more traditional pharmacological approaches. In addition, one can examine the effect of the absence of one cytokine's action on the production and regulation of other cytokines involved in the fever pathway. Of course, there are limitations to the gene knockout approach as well. One must assume that the ability of a particular gene knockout mouse to survive to adulthood is an indication of other cytokines possibly compensating for the loss of the deleted cytokine's action. Although on the one hand this makes the interpretation of negative results from knockout mice problematic, one may also consider this a window of opportunity to further understand the flexibility that is inherent in the physiological networks that regulate fever (and other physiological processes).
The use of knockout mice to study fever is widely used today and has provided important insight into the complex network of cytokine interactions that comprise fever pathways. With this in mind, I will review the current data on cytokines and fever that have been generated with the use of the gene knockout model and, where appropriate, compare and contrast those findings with the results obtained using cytokines and their antagonists. The focus of this review will be mainly on fevers induced by LPS, turpentine, and sepsis.
| |
INTERLEUKIN-1 |
|---|
|
|
|---|
The IL-1 family of ligands consists of IL-1
, IL-1
, and the
IL-1 receptor antagonist (IL-1rn). IL-1
is thought to be the primary secreted form of IL-1, whereas IL-1
is thought to remain mainly cell associated (2). The IL-1rn is an inhibitory
protein that binds to IL-1 receptors without inducing an intracellular signal, thus acting as a true antagonist of IL-1-inducible effects (6). The two receptors for IL-1 have been cloned and are
classified as the type I and type II receptors (38). The
type I receptor is thought to be the only signaling receptor for IL-1,
whereas the type II receptor is thought to serve as a negative
regulator of IL-1 functions (37).
In response to a low dose of LPS, rats and mice develop an ~1°C
fever that lasts 4-8 h after injection. Peripheral injection of
neutralizing antiserum to IL-1
or central microinjection of neutralizing antibodies to IL-1
or IL-1rn attenuates, but does not
eliminate, fevers to a low dose of LPS in rats (14, 26). There are no studies that use IL-1 neutralizing agents that have demonstrated complete inhibition of fever induced by LPS. Is this a
consequence of incomplete inhibition of IL-1 actions with the neutralizing agents or does it merely indicate that IL-1 is only one
mediator in a complex network of regulation? The latter interpretation appears to be the correct one.
Two studies have examined the fever response of IL-1
knockout mice
to the peripheral injection of LPS. In response to a low dose of LPS
(100 µg/kg ip), Kozak et al. (17) found virtually identical fevers in IL-1
knockout and wild-type mice. On the other
hand, Alheim et al. (1) reported enhanced fevers in
IL-1
knockout mice injected with the same dose of LPS. Although
these data are contradictory, they support the hypothesis that IL-1
is not essential for the production of fever to a mild dose of LPS. On
the other hand, in response to a high, septiclike dose of LPS, fevers
were either slightly attenuated (Ref. 17; 2.5 mg/kg ip) or
enhanced (Ref. 1; 5 mg/kg ip) in the IL-1
knockout mice. Reasons for discrepancies in the fever responses of these two
studies are not apparent but may reflect differences in LPS serotype,
LPS dose (see high doses), or the use of different generations and
genetic backgrounds of the knockout mice. Although IL-1
is thought
to induce fever through the production of IL-6, neither knockout study
reported an alteration in LPS-induced plasma levels of IL-6 in the
IL-1
knockout mice.
The caveat to using IL-1
knockout mice to study the fever response
is that IL-1
is still present in these animals and may be able to
bind to the IL-1 type I receptor (IL-1r1) to induce fever, thus
compensating for the lack of IL-1
. To address this issue, we used
IL-1r1 knockout mice to examine the fever response to LPS. Because the
IL-1r1 is the only known signaling receptor for IL-1, neither IL-1
nor IL-1
is able to induce a biological signal in the IL-1r1
knockout mice. We observed virtually identical fevers in the IL-1r1
knockout and wild-type mice in response to both a low (50 µg/kg ip)
and high (2.5 mg/kg ip) dose of LPS (21). Others reported
a slightly attenuated fever response to a low dose (50 µg/kg ip) of
LPS in IL-1r1 knockout mice (19). Despite the
discrepancies between the studies, the data from IL-1
and IL-1r1
knockout mice support the hypothesis that IL-1 is not an essential
mediator of fever and that cytokine redundancy may be responsible for
the lack of effect in some studies.
Turpentine is a model of local inflammation that induces a robust acute
phase response (APR) consisting of fever, anorexia, cachexia, and acute
phase protein production. Pretreatment of mice with a monoclonal
antibody to the IL-1r1 attenuates several of the APR responses to
turpentine (10, 31). Fever was not measured in those
studies but has been examined with the use of both IL-1
and IL-1r1
knockout mice. Subcutaneous injection of turpentine into mice induces a
~2-3°C fever that lasts ~40 h. Fever was shown to be
completely abolished in IL-1
(12, 43) and IL-1r1
(21) knockout mice after injection of turpentine. This is
the first reported elimination of fever after antagonism of endogenous
IL-1 action. Wild-type mice injected with turpentine showed a
significant increase in plasma IL-6 levels that were virtually absent
in the IL-1
knockout mice (43). In fact, all sickness
behaviors associated with the local inflammatory response were
abolished in the IL-1
and IL-1r1 knockout mice, including the
profound anorexia and weight loss. These data support the hypothesis
that the fever and sickness behaviors induced by turpentine are
mediated by IL-1
and its type I receptor.
Overall, data obtained with the IL-1
and IL-1r1 knockout mice are
consistent with the hypothesis that IL-1 plays only a minor role in
fever induced by LPS but is an essential mediator of fever induced by
turpentine. Furthermore, IL-6 production in response to turpentine
appears to be dependent on the presence of IL-1
, whereas LPS is able
to induce IL-6 independently of IL-1
.
| |
INTERLEUKIN-6 |
|---|
|
|
|---|
Several lines of evidence support the hypothesis that IL-6 is an important mediator of fever. First, plasma and brain concentrations of IL-6 have been shown to rise in response to peripheral injections of LPS and turpentine and in patients with sepsis (10, 14, 32). Second, administration of IL-6 into several species induces fever, although the physiological relevance of the injected doses is uncertain (20, 34). Third, fever in response to the peripheral injection of LPS is attenuated after the injection of an IL-6 antibody into the cerebral ventricle of rats (33). However, experiments that used blocking antibodies to IL-6 have been difficult to interpret due to the reported increase in IL-6 half-life and circulating concentration when the antibody complexes with the cytokine (10, 40).
IL-6 knockout mice have been used to study the role of this cytokine in
the fever response to several types of stimuli. IL-6 knockout mice
injected with a low dose (50 µg/kg ip) of LPS were resistant to fever
(4, 17), whereas they developed fevers similar to
wild-type mice after a high dose (2.5 mg/kg ip) of LPS
(17). These data support the hypothesis that the role of IL-6 in the regulation of LPS fever depends on the dose. A high, septiclike dose of LPS may induce the production of additional endogenous pyrogens, which can compensate for a lack of IL-6 in the
knockout mice. IL-6 is thought to act centrally to induce fever, and
Chai et al. (4) reported the ability of centrally injected
IL-6 to induce fever in IL-6 knockout mice, suggesting normal receptor
functioning in those mice. These results suggest that other cytokines,
including IL-11 and leukemia inhibitory factor, that are known to
signal through the IL-6 gp130 receptor may be responsible for fever
generation in the IL-6 knockout mice. The alternative to this
hypothesis is that other cytokines that do not use the IL-6 gp130
receptor, such as IL-8 or MIP-1
, may produce fever in the IL-6
knockout mice as a compensatory response.
Although the injection of LPS is a reasonable model of bacterial infection, the induction of sepsis by the surgical procedure of cecal ligation and puncture (CLP) more closely simulates a clinically relevant bacterial infection. To induce experimental sepsis with CLP, the cecum is exposed and perforated and the intestinal contents are expressed into the peritoneal cavity. CLP induces a reproducible thermoregulatory response that is characterized by an initial hypothermia and a prolonged fever during the 36 h after surgery. Mice deficient in IL-6 developed the initial hypothermia but did not develop fever during sepsis induced by CLP (24). Surprisingly, mortality was significantly enhanced in IL-6 knockout mice despite reports in the literature of high plasma levels of IL-6 negatively correlating with survival. This suggests a permissive action of low levels of IL-6 for survival from sepsis. The difference in the response of IL-6 knockout mice to the high dose of injected LPS and the CLP model may reflect the fact that LPS is a nonproliferating component of gram-negative bacteria, whereas sepsis is the response to proliferating gram-negative and gram-positive bacteria originating in the gut.
As was found for IL-1
and IL-1r1 knockout mice, the injection of
turpentine into IL-6 knockout mice did not induce fever, anorexia, or
body weight loss (17). Thus IL-6 is essential for the
production of fever in response to turpentine. It is unknown whether
IL-1
was produced in response to turpentine in the IL-6 knockout
mice because it was not measured. Fattori et al. (8) showed an increase in IL-1
levels in IL-6 knockout mice injected with turpentine, but others have shown IL-1
knockout mice to develop
virtually identical fevers as wild-type mice to the injection of
turpentine (12). Thus the role of IL-1
in fever to
turpentine is still unresolved.
The data obtained with IL-6 knockout mice support the hypothesis that IL-6 is not essential for all fever responses to bacterial models of infection but is critical for the development of fever, and other APRs, to turpentine.
| |
TUMOR NECROSIS FACTOR |
|---|
|
|
|---|
TNF is a proinflammatory cytokine that exists in two forms,
TNF-
and TNF-
. Both forms induce a number of similar biological effects, but TNF-
is thought to be the main regulator of fever. TNF
interacts with two distinct transmembrane signaling receptors, termed
the p55 (type I) and p75 (type II) receptors, to induce its biological
effects (35, 39). Soluble TNF receptors (sTNFR) also exist
endogenously and act to neutralize the biological activity of TNF
(7).
TNF has been implicated as an endogenous pyrogen due to its ability to
induce fever after injection into several species (13, 29). This effect of TNF likely represents a pharmacological, rather than physiological, effect of the cytokine. The use of neutralizing agents to TNF has demonstrated both pyrogenic and antipyretic activity of this cytokine. In favor of an antipyretic action of TNF-
, Klir et al. (15) reported attenuated
fevers to LPS when rats were treated with a nonpyrogenic dose of
TNF-
(a dose that had no effect on Tb alone) and an
exacerbated fever when the rats were treated with the soluble receptor,
sTNFR. In mice, the early hypothermic phase of fever to a high dose of
LPS was exacerbated by TNF-
treatment, whereas the sTNFR attenuated hypothermia (16). Both of these results are consistent
with TNF action involving a lowering of Tb. Studies
supporting a pyrogenic role for TNF in fever include attenuated fever
to turpentine in rats pretreated with a TNF neutralizing antiserum and
attenuated LPS fever in rabbits treated with a TNF antibody (5,
28).
Data obtained with knockout mice lacking both the TNF p55 and p75 receptors (TNFR knockout mice) support the hypothesis that endogenous TNF either has little role in fever or functions as an endogenous antipyretic, depending on the experimental conditions. Injection of a low dose (50 µg/kg ip) of LPS resulted in no difference in the fever response between TNFR knockout mice and their wild-type controls (22). This finding is not particularly surprising in that lower doses of LPS are not predicted to elicit as profound, and possibly detrimental, rises in Tb that require antagonism by a putative endogenous antipyretic, such as TNF. This is especially relevant in light of the increased resistance of mice to LPS toxicity (i.e., mice require much higher doses of LPS to elicit a profound fever compared with rats). Injection of a high dose (2.5 mg/kg ip) of LPS led to larger fevers in TNFR knockout mice during the early phase (3-15 h) of the febrile response. The enhanced fever in the TNFR knockout mice correlated with decreased plasma levels of endogenous IL-10 at 8 h after LPS injection (11), corresponding to the time of the maximal difference in fever between the TNFR knockout and wild-type mice. These data support the hypothesis that the antipyretic action of TNF during LPS fever is mediated by endogenous IL-10 (see INTERLEUKIN-10, below).
The biphasic Tb response to CLP was differentially altered in the TNFR knockout mice. TNFR knockout mice showed attenuated hypothermia but developed a virtually identical fever as that shown in wild-type mice after CLP (24). These data extend the findings by Kozak et al. (16) to implicate further endogenous TNF in the natural lowering of Tb during the early phase of the fever response. Survival was significantly enhanced in TNFR knockout mice, which corresponds to the reported protective effect of TNF inhibition on the lethality of sepsis in several species (27, 36). These data support the hypothesis that endogenous TNF is responsible for the initial hypothermia and lethality to a bacterial infection in mice. An unaffected fever response in the TNFR knockout mice treated with CLP most likely reflects the late time course for fever development in response to this type of infection. TNF is usually detectable at early time points (~1-2 h), but fever did not develop until ~26 h after CLP. It is likely that the endogenous effects of TNF had dissipated by this time point such that the absence of TNF action in the knockout mice was without effect.
Turpentine induced virtually identical fevers in TNFR knockout and wild-type mice (22). In fact, none of the APRs, including anorexia or cachexia, was altered in TNFR knockout mice. Data obtained with TNFR knockout mice do not support the hypothesis that TNF regulates the APR to turpentine, but cytokine redundancy may have developed in these mice.
In summary, studies that used TNFR knockout mice support an endogenous antipyretic role for TNF in fever. Given a strong systemic stimulus, such as a high dose of LPS or sepsis, TNF functions to lower Tb, thus attenuating fever or producing hypothermia, respectively. TNF does not appear to function in the regulation of a less robust fever, such as that induced by a low dose of LPS. On the other hand, there is little evidence to suggest that endogenous TNF mediates fever to turpentine in mice.
| |
INTERLEUKIN-10 |
|---|
|
|
|---|
IL-10 is a protein product of T helper 2 subset cells that was
originally described as a "cytokine synthesis inhibitory factor." IL-10 inhibits the LPS-induced production of many cytokines implicated in fever, including IL-1
, IL-6, and TNF-
(9).
On the basis of the ability of IL-10 to inhibit the production of
pyrogenic and antipyretic cytokines, many studies have been designed to
examine the role of IL-10 as a regulator of fever. Pharmacologically,
IL-10 functions as an antipyretic. In rats, the central injection of
IL-10 inhibits fever to a peripheral injection of LPS
(30). Similarly, pretreatment of mice with an
intraperitoneal injection of IL-10 significantly attenuates the fever
response to a low (100 µg/kg ip) and high (2.5 mg/kg ip) dose of LPS
(23). To examine the endogenous role of IL-10 in fever, we
injected IL-10 knockout mice with LPS and turpentine. IL-10 knockout
mice injected with a low dose of LPS (50 µg/kg ip) developed an
exacerbated and prolonged fever response (23). Wild-type
mice developed the typical ~4-8 h fever in response to this low
dose of LPS, whereas the IL-10 knockout mice showed a fever response
both the first and second day after injection. To examine the
mechanism(s) responsible for the exacerbated fevers in the knockout
mice, we measured plasma levels of IL-6 and TNF-
at 4 and 24 h
postinjection. These time points corresponded to the time of maximal
fevers in the IL-10 knockout mice. Enhanced plasma levels of IL-6 in
the knockout mice at 4 h postinjection correlated with the
exacerbated fever at this time point, whereas the second-day fever did
not correlate with changes in plasma levels of IL-6 or TNF-
. These
data support the hypothesis that IL-10 has endogenous antipyretic
action during LPS-induced fever due to its ability to inhibit the
production of endogenous IL-6. Interestingly, these data correspond to
the lack of a fever response to a low dose of LPS in IL-6 knockout
mice, again implicating IL-6 as a mediator of fever in this
experimental model (see Ref. 17 and
INTERLEUKIN-6, above). On the other hand, the lack of an
alteration of plasma TNF-
levels in response to the low dose of LPS
correlates with the inability to detect differences in fever to this
same dose of LPS in TNFR knockout mice (see TUMOR NECROSIS
FACTOR, above). The mechanism for the prolonged, second-day fever
response in the IL-10 knockout mice is currently unresolved.
Fever in response to a high dose (2.5 mg/kg ip) of LPS resulted in a profound hypothermia in the IL-10 knockout mice that lasted ~41 h after injection (23). Mortality was significantly enhanced in the knockout mice such that only three animals survived the injection. These data confirm earlier findings of a protective role of IL-10 in septic shock (41).
Data obtained in IL-10 knockout mice support the hypothesis that IL-10 functions as an endogenous antipyretic during LPS fever due to its inhibitory actions on the production of IL-6. IL-10 does not appear to play a role in the regulation of fever to a local inflammation induced by turpentine because IL-10 knockout mice and wild-type mice developed virtually identical fevers (23).
| |
CONCLUSIONS |
|---|
|
|
|---|
Fever is a complex physiological process. The generation of fever is accomplished by the interaction of multiple endogenous mediators, some acting as pyrogens and others as antipyretics. With continuing research on the role of numerous cytokines in fever, our understanding of the regulation of this phenomenon is constantly evolving.
Studies that used traditional pharmacological techniques have supported
the hypothesis that IL-1
and IL-6 are important mediators of fever
to LPS. In almost all instances when IL-1
is pharmacologically antagonized (e.g., injection of an antibody), fever in response to LPS
is attenuated. Furthermore, this attenuation is commonly correlated
with a reduction in IL-6 levels, suggesting that IL-1 induces fever
through the production of IL-6. One criticism of the use of antagonists
is that it is never clear whether the injected substance neutralizes
the action of the cytokine in all areas of the body important for the
regulation of the physiological response, in this case fever.
Furthermore, in many instances, high-quality antagonists for a cytokine
are not commercially available. The use of gene knockout mice to study
fever circumvents these technological limitations and allows the effect
of the elimination of a cytokine's action on fever to be examined.
Data obtained on fever from gene knockout mice have revealed a
redundancy in cytokine action that was not previously recognized. The
pathways depicted in Fig. 2 summarize the
data obtained with gene knockout mice to study fever in response to LPS
and turpentine. Of note, the oversimplification of the fever pathway to
these models of inflammation is only meant to represent the essential components as identified in gene knockout mice. Undoubtedly, other mediators are involved in fever regulation. To develop fever to a low
dose of LPS, IL-6 and IL-10 are required. That is, IL-6 knockout mice
are resistant to fever (17), whereas IL-10 knockout mice
develop exacerbated fevers that correlate with enhanced plasma levels
of IL-6 (23). Thus endogenous IL-6 functions as a pyrogen, whereas IL-10 inhibits the production of IL-6 to act as an endogenous antipyretic. TNF and IL-1 are not essential mediators of fever to this
dose of LPS, because TNFR, IL-1
, and IL-1r1 knockout mice developed
virtually identical fevers as their wild-type controls (17, 21,
22). Figure 2B shows that a high dose of LPS or sepsis induces a different pattern of cytokine regulation. In this
model of fever, IL-1 interacts with the IL-1r1 to produce IL-6 and
fever. The inclusion of IL-1 in this model is based on the attenuated
fever response in IL-1
knockout mice (17). However, there are instances in which IL-1 action is absent yet fevers are
normal, such as in the IL-1r1 knockout mice (21). Under these conditions, fevers are likely due to cytokine redundancy possibly
via the direct production of IL-6 by LPS or the interaction of other
cytokines with the IL-6/gp130 receptor complex (not shown). This latter
explanation is likely responsible for the normal fevers to a high dose
of LPS in IL-6 knockout mice as well, since they still maintain
functional gp130 receptor complexes. The inclusion of IL-6 in this
model of fever reflects the contribution of this cytokine to fever
development during sepsis induced by CLP. IL-6 knockout mice did not
develop fever in response to sepsis (24). The difference
between fever in response to a high dose of LPS and sepsis likely
reflects the presence of proliferating bacteria in the sepsis model. To
inhibit fevers that occur in response to a high dose of LPS or sepsis,
TNF interacts with its p55/p75 receptors. TNFR knockout mice develop
exacerbated fevers in response to a high dose of LPS (22).
This antipyretic action of TNF may be due to the inhibition of IL-6
production by IL-10, although this hypothesis is difficult to test
because of the enhanced sensitivity of IL-10 knockout mice to sepsis
mortality (23). TNFR knockout mice were also resistant to
sepsis-induced hypothermia, further implicating endogenous TNF in the
natural lowering of Tb.
|
The predominant feature of the LPS fever model(s) is the presence of
multiple pathways of cytokine production. The presence of parallel
pathways of cytokine release makes the regulation of fever to LPS
conducive to redundancy. This is in direct contrast to the type of
pathway responsible for fever in response to turpentine. As shown in
Fig. 2B, data obtained with gene knockout mice support a
serial pathway of cytokine production in the regulation of turpentine fever such that the elimination of any component in the pathway eliminates the response. Turpentine induces the production of IL-1, and
IL-1 interacts with the IL-1rtI to induce IL-6 and fever. IL-1
knockout mice do not develop fever or a rise in plasma IL-6 after
turpentine injection (43). Similarly, IL-1rtI and IL-6 knockout mice are resistant to turpentine fever (18, 21). Redundancy is probably not a feature of cytokine regulation of turpentine fever. Although it can be argued that the normal turpentine fever in TNFR and IL-10 knockout mice is the result of cytokine redundancy, there are few data in the literature to suggest that TNF or
IL-10 regulates turpentine fever in mice.
Gene knockout mice provide a unique animal model to study thermoregulatory processes. Several studies have utilized cytokine knockout mice in the study of fever to different stimuli, including LPS, turpentine, and sepsis. It has always been assumed in these studies that the lack of a fever response is the direct result of the missing cytokine's action in these mice. However, an equally plausible explanation for an absent fever response may be the inability of the knockout mouse to develop a fever because of a direct effect of the genetic manipulation on the thermoregulatory controlling center. A critical question to be addressed in any study that uses these mice is whether they are physiologically able to thermoregulate in response to a stimulus. For example, is the absence of fever the result of a deficiency in the afferent pathway (e.g., cytokine signaling) or the efferent pathway (e.g., shivering, vasoconstriction) of thermoregulation? If a particular gene knockout mouse were placed in a thermal gradient to use behavioral thermoregulation to develop a fever, would it show the same fever deficiency to a particular stimulus as it does in the home cage? Although it is assumed that the fever response will be independent of ambient temperature, it is unclear whether the fever responses observed in the gene knockout mice are a direct reflection of alteration in the hypothalamic thermoregulatory set point. However, in most published studies that used cytokine knockout mice, there have been observations of a normal fever response to one stimulus and an altered or absent fever response to another stimulus. These data alone support the hypothesis that the fever-generating mechanisms in these mice are intact and the absence of a response is specific to the missing gene product.
One of the consistent characteristics of gene knockout mice is the absence of gross developmental or phenotypic abnormalities. Circadian rhythms of Tb, reproductive status, and body weight regulation appear to be unaffected in many knockout mice. These observations suggest a redundancy in many of the cytokine actions that have been implicated in developmental processes and normal physiological functioning. Redundancy in cytokine action has been the driving force behind the argument against the use of gene knockout technology to study physiological processes. However, as outlined in this review, there are many circumstances in the same gene knockout mice in which the endogenous actions of a cytokine being studied are compensated in response to one stimulus (e.g., LPS) but not to another (e.g., turpentine). The absence of redundancy under some circumstances may be viewed as an indication of the evolutionary significance of that cytokine's action in the regulation of the response. Our understanding of the complex interaction of cytokines is only enhanced by the use of both pharmacological techniques and gene knockout mice, and these techniques should continue to be used in conjunction to expand our understanding of Tb regulation.
| |
ACKNOWLEDGEMENTS |
|---|
The views, opinions, and/or findings contained in this manuscript are those of the author and should not be construed as an official Department of Army position, policy, or decision.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: L. R. Leon, USARIEM, 42 Kansas St., Natick, MA 01760-5007 (E-mail: lisa.leon{at}na.amedd.army.mil).
10.1152/japplphysiol.01005.2001
| |
REFERENCES |
|---|
|
|
|---|
1.
Alheim, K,
Chai Z,
Fantuzzi G,
Hasanvan H,
Malinowsky D,
Di Santo E,
Ghezzi P,
Dinarello CA,
and
Bartfai T.
Hyperresponsive febrile reactions to interleukin (IL) 1
and IL-1
, and altered brain cytokine mRNA and serum cytokine levels, in IL-1
-deficient mice.
Proc Natl Acad Sci USA
94:
2681-2686,
1997
2.
Auron, PE,
Warner SJ,
Webb AC,
Cannon JG,
Bernheim HA,
McAdam KJ,
Rosenwasser LJ,
LoPreste G,
Mucci SF,
and
Dinarello CA.
Studies on the molecular nature of human interleukin 1.
J Immunol
138:
1447-1456,
1987[Abstract].
3.
Banks, WA,
Kastin AJ,
and
Durham DA.
Bidirectional transport of interleukin-1
across the blood-brain barrier.
Brain Res Bull
23:
433-437,
1989[Web of Science][Medline].
4.
Chai, Z,
Gatti S,
Toniatti C,
Poli V,
and
Bartfai T.
Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1
: a study on IL-6-deficient mice.
J Exp Med
183:
311-316,
1996
5.
Cooper, KW,
Brouwer S,
Turnbull AV,
Luheshi GN,
Hopkins SJ,
Kunkel SL,
and
Rothwell NJ.
Tumor necrosis factor-
and fever after peripheral inflammation in the rat.
Am J Physiol Regulatory Integrative Comp Physiol
267:
R1431-R1436,
1994
6.
Dripps, DJ,
Brandhuber BJ,
Thompson RC,
and
Eisenberg SP.
Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction.
J Biol Chem
266:
10331-10336,
1991
7.
Engelmann, H,
Aderka D,
Rubinstein M,
Rotman D,
and
Wallach D.
A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.
J Biol Chem
264:
11974-11980,
1989
8.
Fattori, A,
Cappalletti M,
Costa P,
Sellitto C,
Cantoni L,
Carelli M,
Faggioni R,
Gantuzzi G,
Ghezzi P,
and
Poli V.
Defective inflammatory response in interleukin 6-deficient mice.
J Exp Med
180:
1243-1250,
1994
9.
Fiorentino, DF,
Zlotnik A,
Mosmann TR,
Howard M,
and
O'Garra A.
IL-10 inhibits cytokine production by activated macrophages.
J Immunol
147:
3815-3822,
1991[Abstract].
10.
Gershenwald, JE,
Fong Y,
Fahey TJ, III,
Calvano SE,
Chizzonite R,
Kilian PL,
Lowry SF,
and
Moldawer LL.
Interleukin 1 receptor blockade attenuates the host inflammatory response.
Proc Natl Acad Sci USA
87:
4966-4970,
1990
11.
Gourine, AV,
Leon LR,
Rudolph K,
Tesfaigzi J,
and
Kluger MJ.
Cytokine cascade induced by endotoxin in TNF double receptor knockout mice: evidence supporting a role for IL-10 in mediating antipyretic action of TNF.
J Therm Biol
25:
21-27,
2000.
12.
Horai, R,
Asano M,
Sudo K,
Kanuka H,
Suzuki M,
Nishihara M,
Takahashi M,
and
Iwakura Y.
Production of mice deficient in genes for interleukin (IL)-1
, IL-1
, IL-1
/
,and IL-1 receptor antagonist shows that IL-1
is crucial in turpentine-induced fever development and glucocorticoid secretion.
J Exp Med
187:
1463-1475,
1998
13.
Kettelhut, IC,
and
Goldberg AL.
Tumor necrosis factor can induce fever in rats without activating protein breakdown in muscle or lipolysis in adipose tissue.
J Clin Invest
81:
1384-1389,
1988[Web of Science][Medline].
14.
Klir, JJ,
McClellan JL,
and
Kluger MJ.
Interleukin-1
causes the increase in anterior hypothalamic interleukin-6 during LPS-induced fever in rats.
Am J Physiol Regulatory Integrative Comp Physiol
266:
R1845-R1848,
1994
15.
Klir, JJ,
McClellan JL,
Kozak W,
Szelenyi Z,
Wong GHW,
and
Kluger MJ.
Systemic, but not central, administration of tumor necrosis factor
attenuates LPS-induced fever in rats.
Am J Physiol Regulatory Integrative Comp Physiol
268:
R480-R486,
1995
16.
Kozak, W,
Conn CA,
Klir JJ,
Wong GWH,
and
Kluger MJ.
TNF soluble receptor and antiserum against TNF enhance lipopolysaccharide fever in mice.
Am J Physiol Regulatory Integrative Comp Physiol
269:
R23-R29,
1995
17.
Kozak, W,
Kluger MJ,
Soszynski D,
Conn CA,
Rudolph K,
Leon LR,
and
Zheng H.
IL6 and IL1
in fever. Studies using cytokine-deficient (knockout) mice.
Ann NY Acad Sci
856:
33-47,
1998[Web of Science][Medline].
18.
Kozak, W,
Poli V,
Soszynski D,
Conn CA,
Leon LR,
and
Kluger MJ.
Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis.
Am J Physiol Regulatory Integrative Comp Physiol
272:
R621-R630,
1997
19.
Labow, M,
Shuster D,
Zetterstrom M,
Nunes P,
Terry R,
Cullinan EB,
Bartfai T,
Solorzano C,
Moldawer LL,
Chizzonite R,
and
McIntyre KW.
Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice.
J Immunol
159:
2452-2461,
1997
20.
LeMay, L,
Vander AJ,
and
Kluger MJ.
The role of IL-6 in fever in the rat.
Am J Physiol Regulatory Integrative Comp Physiol
258:
R798-R803,
1990
21.
Leon, LR,
Conn CA,
Glaccum M,
and
Kluger MJ.
IL-1 type I receptor mediates acute phase response to turpentine, but not lipopolysaccharide, in mice.
Am J Physiol Regulatory Integrative Comp Physiol
271:
R1668-R1675,
1996
22.
Leon, LR,
Kozak W,
Peschon J,
and
Kluger MJ.
Exacerbated febrile responses to LPS, but not turpentine, in TNF double receptor-knockout mice.
Am J Physiol Regulatory Integrative Comp Physiol
272:
R563-R569,
1997
23.
Leon, LR,
Kozak W,
Rudolph K,
and
Kluger MJ.
An antipyretic role for interleukin-10 in LPS fever in mice.
Am J Physiol Regulatory Integrative Comp Physiol
276:
R81-R89,
1999
24.
Leon, LR,
White AA,
and
Kluger MJ.
Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice.
Am J Physiol Regulatory Integrative Comp Physiol
275:
R269-R277,
1998
25.
Liebermeister, C.
Vorlesungen Uber Specielle Pathologie und Therapie. Lepzig, Germany: Verlag-Vogel, 1887.
26.
Luheshi, G,
Miller AJ,
Brouwer S,
Dascombe MJ,
Rothwell NJ,
and
Hopkins SJ.
Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6 induction in the rat.
Am J Physiol Endocrinol Metab
270:
E91-E105,
1996
27.
Lundblad, R,
Ekstrom P,
and
Giercksky KE.
Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats.
Shock
3:
210-215,
1995[Web of Science][Medline].
28.
Nagai, M,
Saigusa T,
Shimada Y,
Inagawa H,
Oshima H,
and
Iriki M.
Antibody to tumor necrosis factor (TNF) reduced endotoxin fever.
Experientia
44:
606-607,
1988[Web of Science][Medline].
29.
Nakamura, H,
Seto Y,
Motoyoshi S,
Kadokawa T,
and
Sunahara N.
Recombinant human tumor necrosis factor causes long-lasting and prostaglandin-mediated fever, with little tolerance, in rabbits.
J Pharmacol Exp Ther
245:
336-341,
1988
30.
Nava, F,
Calapai G,
Facciola G,
Cuzzocrea S,
Marciano MC,
De Sarro A,
and
Caputi AP.
Effects of interleukin-10 on water intake, locomotor activity, and rectal temperature in rat treated with endotoxin.
Int J Immunopharmacol
19:
31-38,
1997[Web of Science][Medline].
31.
Oldenburg, HAS,
Rogy MA,
Lazarus DD,
Van Zee KJ,
Keeler BP,
Chizzonite RA,
Lowry SF,
and
Moldawer LL.
Cachexia and acute-phase protein response in inflammation are regulated by interleukin-6.
Eur J Immunol
23:
1889-1894,
1993[Web of Science][Medline].
32.
Patel, RT,
Deen KI,
Youngs D,
Warwick J,
and
Keighley MRB
Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis.
Br J Surg
81:
1306-1308,
1994[Web of Science][Medline].
33.
Rothwell, NJ,
Busbridge NJ,
Lefeuvre RA,
Hardwick AJ,
Gauldie J,
and
Hopkins SJ.
Interleukin-6 is a centrally acting endogenous pyrogen in the rat.
Can J Physiol Pharmacol
69:
1465-1469,
1991[Web of Science][Medline].
34.
Sakata, Y,
Morimoto A,
Long NC,
and
Murakami N.
Fever and acute-phase response induced in rabbits by intravenous and intracerebroventricular injection of interleukin-6.
Cytokine
3:
199-203,
1991[Web of Science][Medline].
35.
Schall, TJ,
Lewis M,
Koller KJ,
Lee A,
Rice GC,
Wong GH,
Gatanaga T,
Granger GA,
Lentz R,
and
Raab H.
Molecular cloning and expression of a receptor for human tumor necrosis factor.
Cell
61:
361-370,
1990[Web of Science][Medline].
36.
Silva, AT,
Bayston KF,
and
Cohen J.
Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-
in experimental gram-negative shock.
J Infect Dis
162:
421-427,
1990[Web of Science][Medline].
37.
Sims, JE,
Gayle MA,
Slack JL,
Alderson MR,
Bird TA,
Giri JG,
Colotta F,
Re F,
Mantovani A,
Shanebeck K,
Grabstein KH,
and
Dower SK.
Interleukin-1 signaling occurs exclusively via the type I receptor.
Proc Natl Acad Sci USA
90:
6155-6159,
1993
38.
Sims, JE,
Giri JG,
and
Dower SK.
The two interleukin-1 receptors play different roles in IL-1 actions.
Clin Immunol Immunopathol
72:
9-14,
1994[Web of Science][Medline].
39.
Smith, CA,
Davis T,
Anderson D,
Solam L,
Beckmann MP,
Jerzy R,
Dower SK,
Cosman D,
and
Goodwin RG.
A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.
Science
248:
1019-1023,
1990
40.
Strassman, G,
Fong M,
Kenney JS,
and
Jacob CO.
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
J Clin Invest
89:
1681-1684,
1992[Web of Science][Medline].
41.
Van der Poll, T,
Marchant A,
Buurman WA,
Berman L,
Keogh CV,
Lazarus DD,
Nguyen L,
Goldman M,
Moldawer LL,
and
Lowry SF.
Endogenous IL-10 protects mice from death during septic peritonitis.
J Immunol
155:
5397-5401,
1995[Abstract].
42.
Watkins, LR,
Goehler LE,
Relton JK,
Tartaglia N,
Silbert L,
Martin D,
and
Maier SF.
Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication.
Neurosci Lett
183:
27-31,
1995[Web of Science][Medline].
43.
Zheng, H,
Fletcher D,
Kozak W,
Jiang M,
Hofmann KJ,
Conn CA,
Soszynski D,
Grabiec C,
Trumbauer ME,
Shaw A,
Knockoutstura MJ,
Stevens K,
Rosen H,
North RJ,
Chen HY,
Tocci MJ,
Kluger MJ,
and
Van der Ploeg LHT
Resistance to fever induction and impaired acute-phase response in interleukin-1
-deficient mice.
Immunity
3:
9-19,
1995[Web of Science][Medline].
This article has been cited by other articles:
![]() |
M Hirao, J Hashimoto, H Tsuboi, A Nampei, H Nakahara, N Yoshio, T Mima, H Yoshikawa, and N Nishimoto Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab Ann Rheum Dis, May 1, 2009; 68(5): 654 - 657. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Yura, S. G. Bradley, G. Ramesh, W. B. Reeves, and J. S. Bond Meprin A metalloproteases enhance renal damage and bladder inflammation after LPS challenge Am J Physiol Renal Physiol, January 1, 2009; 296(1): F135 - F144. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Noisakran and G. C. Perng Alternate Hypothesis on the Pathogenesis of Dengue Hemorrhagic Fever (DHF)/Dengue Shock Syndrome (DSS) in Dengue Virus Infection Experimental Biology and Medicine, April 1, 2008; 233(4): 401 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Aguilar-Valles, S. Poole, Y. Mistry, S. Williams, and G. N. Luheshi Attenuated fever in rats during late pregnancy is linked to suppressed interleukin-6 production after localized inflammation with turpentine J. Physiol., August 15, 2007; 583(1): 391 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Benzaquen, C. A. Risco, L. F. Archbald, P. Melendez, M.-J. Thatcher, and W. W. Thatcher Rectal Temperature, Calving-Related Factors, and the Incidence of Puerperal Metritis in Postpartum Dairy Cows J Dairy Sci, June 1, 2007; 90(6): 2804 - 2814. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Boelen, J Kwakkel, W M Wiersinga, and E Fliers Chronic local inflammation in mice results in decreased TRH and type 3 deiodinase mRNA expression in the hypothalamic paraventricular nucleus independently of diminished food intake J. Endocrinol., December 1, 2006; 191(3): 707 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Samardzija, A. Wenzel, M. Thiersch, R. Frigg, C. Reme, and C. Grimm Caspase-1 Ablation Protects Photoreceptors in a Model of Autosomal Dominant Retinitis Pigmentosa Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5181 - 5190. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Boelen, J. Kwakkel, A. Alkemade, R. Renckens, E. Kaptein, G. Kuiper, W. M. Wiersinga, and T. J. Visser Induction of Type 3 Deiodinase Activity in Inflammatory Cells of Mice with Chronic Local Inflammation Endocrinology, December 1, 2005; 146(12): 5128 - 5134. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Borner, J. Kraus, H. Schroder, H. Ammer, and V. Hollt Transcriptional Regulation of the Human {micro}-Opioid Receptor Gene by Interleukin-6 Mol. Pharmacol., December 1, 2004; 66(6): 1719 - 1726. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mouihate, L. Boisse, and Q. J. Pittman A Novel Antipyretic Action of 15-Deoxy-{Delta}12,14-Prostaglandin J2 in the Rat Brain J. Neurosci., February 11, 2004; 24(6): 1312 - 1318. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |